As previously reported, RBC Capital downgraded Regeneron (REGN) to Sector Perform from Outperform with a price target of $662, down from $943, following “disappointing” itepekimab results given the firm’s sense that the path forward for that drug “may be limited.” The firm still likes the long-term prospects of the company’s R&D engine and believes shares are likely fundamentally undervalued, so it “would not be surprised to see shares rebound off of lows.” However, RBC believes substantial outperformance in the near term beyond this would require success of a pipeline drug with similar multi-billion dollar potential to itepekimab and/or “major and well-received” external business development, which does not “seem imminent,” the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Regeneron downgraded to Sector Perform from Outperform at RBC Capital
- Airbnb, Zscaler downgraded: Wall Street’s top analyst calls
- Regeneron downgraded to Equal Weight from Overweight at Wells Fargo
- Wells Fargo downgrades Regeneron after ‘disappointing’ itepekimab data
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue